On August 25, 2023 Taiho Pharmaceutical Co., Ltd. (Taiho Pharmaceutical) and Phost’in Therapeutics SAS (Phost’in) reported that the two companies have entered into an option and license agreement through which Taiho Pharmaceutical will obtain option rights to inlicense PhOx430, a First-in-Class small molecule targeting GnT-V (Nacetylglucosaminyltransferase-V) (Press release, Taiho, AUG 25, 2023, View Source [SID1234634697]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
According to the terms of this agreement, Taiho Pharmaceutical will make an upfront payment to Phost’in. In return, Taiho Pharmaceutical will receive an option right to inlicense PhOx430 and additional undisclosed compounds and to exclusively develop and commercialize the compounds in Japan and certain other territories in Asia (excluding China). When Taiho Pharmaceutical will exercise its option right, the company will make an option exercise payment, as well as additional payments upon achievement of clinical, regulatory and commercial milestones. The company will also pay royalties on net sales in its regions.
Phost’in retains the right to develop and commercialize the licensed compounds in other territories, including North America, Europe and China and will be in charge of manufacturing.
"We believe in the potential of Phost’in Therapeutics’s cutting-edge technologies targeting N-glycosylation to bring benefit to the patients in the oncology and fibrosis areas. This agreement resonates with our vision of supporting innovative and highly valuable new drugs to accelerate R&D for significant unmet needs," said Atsushi Azuma, Managing Director at Taiho Pharmaceutical.
Karine Chorro, CEO of Phost’in Therapeutics, remarked "We are very pleased to announce this collaboration with Taiho Pharmaceutical, a leading pharmaceutical company in the oncology area. This demonstrates the value of our targeted first-in-class, small molecule Gnt-V inhibitor approach to the treatment of solid tumours in cancer. We are eager to continue developing this novel approach in collaboration with our new partner".
About PhOx430
PhOx430 is a First-in-Class N-glycosylation inhibitor, designed to target GnT-V, a key nglycosylation enzyme responsible for suppressing the immune response and supporting cancer proliferation as well as formation of fibrotic tissues. PhOx430 is currently evaluated in Europe in a Phase I/II in patients with advanced solid tumors (the PhAST trial). It is also the first program from the Phost’ScreenTM platform that combines unique and patented chemical libraries with cutting-edge screening tools to produce selective nglycosylation inhibitors for the treatment of cancer and other serious immunoinflammatory diseases.